Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CV301 + nivolumab
- Development stage
- Unknown
- Lead developer
- Bavarian Nordic
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
CV301 is a poxviral-based cancer vaccine that targets the tumor-associated antigens carcinoembryonic antigen (CEA) and mucin 1 (MUC1), which are overexpressed in multiple solid tumors. It uses a prime/boost dosing schedule with an initial priming dose of modified vaccinia Ankara-BN-CV301 (MVA) followed by boosting doses of fowlpox-CV301 (FPV). The combination with nivolumab—an anti-PD-1 monoclonal antibody checkpoint inhibitor—aims to enhance T cell-mediated immune responses against cancer cells by combining vaccine-induced tumor-specific immunity with blockade of the PD-1 inhibitory pathway[5][6][7]. This combination has been evaluated in clinical trials for advanced non-small cell lung cancer and metastatic colorectal cancer.
- Other names
- PANVAC (former version of CV301)modified vaccinia Ankara-BN-CV301fowlpox-CV301fowlpox-CV-301fowlpox-CV 301
02
Targets
MUC1 (Mucin-1 Antigen)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on CV301 + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CV301 + nivolumab.